In this video, Dr. Paul Richardson (Dana Farber Cancer Institute, Boston) talks about the most exciting multiple myeloma clinical abstracts presented at ASCO 2019.

Updated risk stratification model for smoldering multiple myeloma (SMM) incorporating the revised IMWG diagnostic criteria. The risk stratification model for smoldering multiple myeloma incorporates revised cutoffs for previously used parameters (20/2/20) that can be universally applied. Additional analysis is being conducted to develop models that utilize common cytogenetic abnormalities, as well as those without FLC given lack of availability of tests across the world. 
ASCO 2019 Abstract No: 8000 Citation: J Clin Oncol 37, 2019 (suppl; abstr 8000)

E3A06: Randomized phase III trial of lenalidomide versus observation alone in patients with asymptomatic high-risk smoldering multiple myeloma. This trial found that early therapy with lenalidomide prevented end-organ damage and had no adverse impact on the quality of life. 
ASCO 2019 Abstract No: 8001 Clinical trial information: NCT01169337 Citation: J Clin Oncol 37, 2019 (suppl; abstr 8001)

Phase 3 randomized study of daratumumab (DARA) + bortezomib/thalidomide/dexamethasone (D-VTd) vs VTd in transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): CASSIOPEIA Part 1 results. In conclusion, daratumumab + bortezomib/thalidomide/dexamethasone in induction prior to and consolidation after ASCT improved depth of response (sCR, ≥CR, and MRD negativity) and PFS with acceptable safety. The favorable benefit-risk profile supports the use of D-VTd in transplant-eligible newly diagnosed multiple myeloma. CASSIOPEIA is the first study to demonstrate the clinical benefit of DARA + SoC in transplant-eligible newly diagnosed multiple myeloma.
ASCO 2019 Abstract No: 8003 Clinical trial information: NCT02541383 Citation: J Clin Oncol 37, 2019 (suppl; abstr 8003)

First clinical (phase 1b/2a) study of iberdomide (CC-220; IBER), a CELMoD, in combination with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM). A trial of the new drug category CC220, a new compound made by Celgene, shows significant improvement in relapsed and refractory patients.
ASCO 2019 Abstract No: 8006 Clinical trial information: NCT02773030 Citation: J Clin Oncol 37, 2019 (suppl; abstr 8006)

Local activator and T cell engager (LocATE) selectively blocks PD-L1 at the cytolytic synapse for deeper responses in multiple myeloma. The trial results suggest that T cell redirection with simultaneous checkpoint inhibition in the synapse is highly potent while minimizing off-tumor toxicity, therefore, has high therapeutic potential for patients with relapsed MM.
ASCO 2019 Abstract No: 8045 Citation: J Clin Oncol 37, 2019 (suppl; abstr 8045)


Paul Richardson, M.D. is the Clinical Program Leader and Director of Clinical Research at the Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute in Boston. He is also an Institute Physician and a RJ Corman Professor of Medicine, at Harvard Medical School in Cambridge, MA. In addition to multiple myeloma, his key clinical interests are regimen-related toxicity, stem cell transplantation, experimental therapies and cancer pharmacology, and more. Visit Dr. Paul Richardson’s full biography.


Previous Post
Efficacia della KRD con o senza trapianto nel mieloma di nuova diagnosi: FORTE
Next Post
Safety and efficacy of once-weekly carfilzomib dosing in frail patients

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.